/
ONCY
$0.96+$0.01 (+1.45%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$113.1M
119M shares
52-week range
$0.71 – $1.51
31% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
9.36%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $95.4K | $485.6K | $332.7K | $360.6K | $301.1K | $298.6K | $87.0K | $70.0K |
| Gross profit | −$95.4K | −$485.6K | −$332.7K | −$360.6K | −$301.1K | −$298.6K | −$87.0K | −$70.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $9.4M | $10.8M | $9.7M | $10.3M | $11.9M | $13.1M | $21.6M | $18.3M |
| Operating income | −$16.7M | −$20.7M | −$19.0M | −$20.9M | −$20.7M | −$25.0M | −$35.0M | −$39.4M |
| EBITDA | −$17.2M | −$19.7M | −$16.4M | −$20.6M | −$18.7M | −$20.2M | −$34.9M | −$39.4M |
| Net income | −$17.0M | −$45.6M | −$16.8M | −$21.0M | −$19.1M | −$20.6M | −$31.7M | −$39.5M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.06 | -1.50 | -0.48 | -0.49 | -0.44 | -0.41 | -0.41 | -0.41 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-0.34 | $-0.38–$-0.31 | 3 |
| 2027 | $594629 | $-0.29 | $-0.35–$-0.23 | 4 |
| 2028 | $13M | $-0.21 | $-0.21–$-0.21 | 3 |
| 2029 | $72M | $0.02 | $0.02–$0.02 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.02
Price
$0.96
Implied downside
-98%
Peer comparison
Oncolytics Biotech, Inc. Common Shares
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
www.oncolyticsbiotech.com- Employees
- 29
- IPO / List date
- Oct 5, 2001
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ONCY.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ONCY as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ONCY yet.
